This site is intended for healthcare professionals
News

Results from phase III CROWN trial of Lorbrena for previously untreated ALK + lung cancer is published in NEJM.- Pfizer

Read time: 2 mins
Last updated:20th Nov 2020
Published:20th Nov 2020
Condition: NSCLC/ ALK+
Type: drug
Register free for full access to medthority.com